Does vaginal delivery of combined hormonal contraception affect

Recruiting

99 years or below

All

40 participants needed

1 Location

Brief description of study

This research study is being conducted to determine if there is an effect on the development of Metabolic Syndrome (MetS) in women with PCOS when using NuvaRing. This study will recruit 40 women between the ages of 18-40, with a diagnosis of PCOS, NO diagnosis of MetS, and a BMI between 25 and 45. Women will be asked to use NuvaRing for 4 months. They will have fasting bloodwork (including OGTT) at baseline and four months, and will be contacted once a month by research staff.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Polycystic Ovary Syndrome, PCOS
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 834422

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Does vaginal delivery of combined hormonal contraception affect the risk of metabolic syndrome in overweight/obese women with PCOS?

Brief description of study

Eligibility of study

Find a site

Interested in the study